Structure Prediction and In-silico Designing of Drugs against Plant Homeodomain Finger Protein 14 for Suppression of Malignant Transformation and Tumorigenicity of Non Small Cell Lung Cancer

Author:

Devgun Manish1,Nandini Nandini2,Singh Lalit3,Sharma Saurabh4

Affiliation:

1. Institute of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra, Haryana – 136119.

2. Rajshree Medical Research Institute, Bareilly, Uttar Pradesh – 243501.

3. Department of Pharmacy, Invertis University, Bareilly, Uttar Pradesh – 243123.

4. Vivek College of Technical Education, Bijnor, Uttar Pradesh – 246701.

Abstract

PHF14 (PHD finger protein 14) is associated with Plant Homeodomain (PHD) Finger Protein family. This chromatin-binding protein interacts with histones. PHF14 overexpression has gained attention due to compelling evidence of its involvement in cell proliferation of various cell lines. PHF14 plays a critical function in the induction of pulmonary fibrosis, and actively participate in cell mitosis which makes it a probable target in the treatment of lung fibrosis and can also be utilized as a biomarker in evaluation and management of non small cell lung cancer. A model of PHF14 protein was prepared by homology modelling and was verified by Ramachandran plot. This model of PHF14 protein was acknowledged by Protein Model Data Base (PMDB) and has been assigned PMDB ID: PM0084114. The DrugBank database was used to obtain ligands, to dock against PHF14 by applying PatchDock technique. The structure of the selected ligand (DB08438) was then modified by means of ACD/ChemSketch 8.0 to secure 22 new in silico ligands, which were subjected to the docking procedure. The docking results identify ligand 31 to possess a high binding affinity with the target protein. The in silico docking results suggests that ligands 31, 12, 13, 14, 15, 16, 18, 19, 20, 21, 22, 23, 26, 29, 30, 31, 32, and 33 have a high preference for binding with PHF14 and these compounds should be thoroughly probed so as to develop potential chemical entities for the suppression of malignant transformation and tumorigenicity of non small cell lung cancer.

Publisher

A and V Publications

Subject

Pharmacology (medical),Pharmacology, Toxicology and Pharmaceutics (miscellaneous)

Reference48 articles.

1. Malik PS, Raina V. Lung cancer: prevalent trends & emerging concepts. Indian J Med Res. 2015;141(1):5-7. doi: 10.4103/0971-5916.154479.

2. Valatina GM, Livinsa ZM. SBIR based screening for lung cancer. Research J Pharm and Tech. 2019;12(1):62-6. doi: 10.5958/0974-360X.2019.00012.X.

3. Yoder LH. An overview of lung cancer: symptoms, pathophysiology and treatment. Medsurg Nurs. 2006;15(4):231-4.

4. Dwivedi N, Dwivedi B, Mishra S, Shukla Y. Lupeol induced apoptosis in human lung cancer cell line: a flow cytometry study. Research Journal of Pharmacology and Pharmacodynamics. 2014;6(4):197-203.

5. Gayathri K, Vaidhehi V. An automatic identification of lung cancer from different types of medical images. Res J Pharm Tech. 2019;12(5):2109-15. doi: 10.5958/0974-360X.2019.00350.0

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3